Ascentage Pharma Group International (HK:6855) has released an update.
Ascentage Pharma Group International announced positive clinical results for olverembatinib and lisaftoclax at the 2024 European Hematology Association Hybrid Congress. The studies showed that olverembatinib is effective and well-tolerated in patients with chronic myeloid leukemia and acute lymphoblastic leukemia, even those resistant to other treatments. These developments could be significant for investors looking at novel therapies in the hematology space.
For further insights into HK:6855 stock, check out TipRanks’ Stock Analysis page.
